PORT WASHINGTON, N.Y. – June 15, 2015 – Pall Corporation (NYSE:PLL), a global leader in filtration, separation and purification, announced the signing of an exclusive license for acoustic wave separation (AWS), a disruptive technology from FloDesign Sonics (FDS) for cell culture clarification for both fed-batch and perfusion applications. The AWS technology enables very-high-efficiency continuous removal of the cells in a closed system without centrifugation, thereby streamlining a challenging step in the biologics manufacturing process within a small operating footprint. The technology will complement Pall's industry-leading STAXTM depth filtration products to enable continuous clarification of cell culture, enabling integration of the bioreactor with downstream processing.
The AWS technology works by applying acoustic forces across a flow channel to generate a three-dimensional standing wave. When a cell culture passes through the flow channel, the cells are trapped at the nodes of the acoustic waves and then aggregate, culminating in their precipitation from suspension as their buoyancy decreases. Important features are no temperature increase, no damage to cells or proteins, and the process works in a robust manner at high yields.
The integration of the AWS technology expands the portfolio of continuous bioprocessing and single-use products offered by Pall, which recently announced the acquisition of the BioSMB® multicolumn continuous chromatography platform from Tarpon Biosystems. "This approach helps to bridge the critical gap between bioreactor and the downstream processing train," says Michael Egholm, president of Pall Biopharmaceuticals. "The AWS products will eliminate the reliance on centrifugation for cell culture clarification, and will provide a continuous feed stream for direct integration with the BioSMB platform.”
Both technologies will be featured in the Pall booth at ACHEMA in Frankfurt, June 15 to 19, as part of  the “Continuously Improving Bioprocessing” theme. Pall plans to introduce a single-use product line using AWS technology for the clarification of cell culture at both bench scale and GMP scale to match pilot and production bioreactor volumes, with predictable and reproducible performance over a wide range of cell densities. Over the coming months, Pall will engage with industry thought leaders in evaluation of the AWS technology and its benefits.

About Pall Corporation
Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 Company serving customers worldwide. Follow us on Twitter @PallCorporation or visit www.pall.com.

Marketing Contact
Erin C. Bush
Senior Manager, Product Marketing
Pall Life Sciences
Telephone: +1 516.801.9637
Email: Erin_Bush@pall.com
Public Relations
Beth Willers, Account Director
Impress Labs
Telephone: +1 415.846.9891
Email: beth@impresslabs.com

More Biotech Press Releases
Read all the latest news and developments from Pall and keep in touch with industry trends and opinion.
April 2020
Pall joins a consortium led by Oxford University in fast-tracking clinical trials for a COVID-19 vaccine beginning April 2020.